Selective μ receptor agonist
PZM21 is a selective μ receptor agonist (EC50 = 4.6 nM). PZM21 has been reported to exhibit bias for the Gi signaling pathway over arrestin-3. The compound exhibits 500-fold selectivity for μ over δ receptors and no detectable activity at κ or nociceptin receptors and a panel of 316 other GPCRs. PZM21 induces analgesia in a mouse hot plate assay, but not a tail-flick assay and exhibits no significant conditioned place preference response in
in vivo
assays. CNS penetrant.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125759 |
| Réf. fabricant | 18769576 |
| Nom chimique ou matériau | N-[(2 S)-2-(Dimethylamino)-3-(4-hydroxyphenyl)propyl]-N'-[(1 S)-1-methyl-2-(3-thienyl)ethyl]urea |
| CAS | 1997387-43-5 |
| Quantité | 50 mg |
| Cible | mu Opioid Receptor Agonists |
| Formule moléculaire | C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>S |
| Pureté | 0.98 |
